

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6954038

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	PURETECH MANAGEMENT, INC.	09/01/2021
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	PURETECH HEALTH LLC	
<b>Street Address:</b>	6 TIDE ST.	
<b>City:</b>	BOSTON	
<b>State/Country:</b>	MASSACHUSETTS	
<b>Postal Code:</b>	02210	
<b>PROPERTY NUMBERS Total: 3</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	62896235	
<b>Application Number:</b>	62959648	
<b>PCT Number:</b>	US2020014858	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(716)849-0349	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	716.856.4000	
<b>Email:</b>	rwatt@hodgsonruss.com	
<b>Correspondent Name:</b>	RACHEL S. WATT	
<b>Address Line 1:</b>	HODGSON RUSS LLP	
<b>Address Line 2:</b>	140 PEARL STREET, SUITE 100	
<b>Address Line 4:</b>	BUFFALO, NEW YORK 14202-4040	
<b>ATTORNEY DOCKET NUMBER:</b>	058636.00256	
<b>NAME OF SUBMITTER:</b>	RACHEL S. WATT	
<b>SIGNATURE:</b>	/rachel s. watt#46186/	
<b>DATE SIGNED:</b>	10/05/2021	
<b>Total Attachments: 4</b>		
source=LYT210cyno_PTM_to_PTH#page1.tif		
source=LYT210cyno_PTM_to_PTH#page2.tif		
source=LYT210cyno_PTM_to_PTH#page3.tif		



## ASSIGNMENT

This ASSIGNMENT is entered into by and between PureTech Management, Inc., (“Assignor”), a Delaware corporation, and PureTech Health LLC (“Assignee”), a Delaware limited liability corporation.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, the undersigned parties agree as follows:

1. Assignor does hereby sell, assign, transfer and convey unto the Assignee, and/or confirm prior assignment, transfer, or conveyance unto the Assignee, the entire right, title and interest in the invention described and claimed in the patents and applications listed on Annex A filed in the United States Patent and Trademark Office (hereinafter “Assigned Patent Applications”), and Assignee hereby ratifies and confirms the assumption and acceptance of, all of Assignor’s worldwide right, title, and interest in and to: (a) such Assigned Patent Applications, together with all registrations and applications for the foregoing; and all rights to request, apply for, file and register patent rights in any of the foregoing; (b) all applications, including provisional applications, continuation applications, divisional applications, substitute applications and continuation-in-part applications claiming the benefit of the filing date of or priority to the foregoing; all patents of addition of the foregoing; all continued examinations, re-examinations, inter partes review and post-grant review certificates of the foregoing; (c) all validations, supplementary protection certifications and extensions of the foregoing; (d) all inventions disclosed or claimed by any of the foregoing; (e) all rights to claim priority to the foregoing under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, and applicable bilateral or multilateral treaties; (f) all patents issuing from the foregoing and all amendments, reissues, and extensions of the foregoing; (g) all defenses relating to or arising from any of the foregoing, and all rights of actions arising from the foregoing, including without limitation all claims for damages by reason of infringement or violation of the foregoing and all present, past and future rights to sue and collect damages or seek injunctive relief for any such infringement or violation of the foregoing; and (h) all income, royalties and any other payments now and hereafter due and/or payable to in respect of the foregoing, in each case, to be held and enjoyed by Assignee for its own use and benefit and for its successors, legal representatives, and assigns as the same would have been held as fully and entirely by Assignor had this assignment not been made (collectively, the “Assigned Patent Application Rights”).

2. Assignor hereby confirms that, at the time of invention, except for any rights, titles and/or interests that have arisen to Assignee under law or that had already been transferred to Assignee, ownership of the entire right, title, and interest in and to the said Assigned Patent Applications were conveyed to Assignor, and that the Assignor was unencumbered and had good and full right and lawful authority to convey the same to Assignee.

3. To the extent that any of its rights to the Assigned Patent Applications were not assigned, Assignor hereby assigns all of its right, title and interest to the Assigned Patent Applications to the Assignee, including the Assigned Patent Application Rights.

4. Assignor shall promptly execute and deliver such documents, and do and perform such acts and things as Assignee, its successors, legal representatives and/or assigns may reasonably request to give effect to, document and record, perfect and enforce the assignment of the Assigned Patent Application Rights herein recited, including without limitation executing and delivering such other documents as may be required to give full effect to and to perfect the rights of Assignee, its successors, legal representatives and assigns under this Patent Assignment in and to the Assigned Patent Application Rights worldwide.

5. Assignor further agrees, at any time, upon the reasonable request of Assignee, its successors, legal representatives and/or assigns, to execute and deliver same, any additional applications for patent arising from or relating to the Assigned Patent Application Rights, or any part or parts thereof, including without limitation any provisional, utility, design, continuation, continuation-in-part, divisional, reissue, substitute, and extension application(s) to the foregoing; and all re-examination, inter partes, post-grant and opposition certification(s) or amendments or reissues of the foregoing and all patent application(s) claiming benefit of or priority from the foregoing; and all patents issued from the foregoing. Assignor further confirms that Assignor has not made any agreement in conflict with this Patent Assignment.


6. Assignor hereby grants Assignee the power to insert on this assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark office for recordation of this document.

7. This Patent Assignment shall be binding upon and inure to the benefit of the parties hereto and their respective successors, legal representatives and assigns. As between the parties, this Patent Assignment and any claim, controversy, dispute or cause of action (whether in contract, tort or otherwise) based upon, arising out of or relating to this Patent Assignment shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts applicable to agreements made and to be performed entirely within the Commonwealth of Massachusetts, without regard to the conflicts of laws principles thereof.


8. This Patent Assignment may be executed in the original or by facsimile in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

As read and agreed to by:

**PURETECH MANAGEMENT, INC. (“Assignor”)**

By:   
575C896D138A48D...  
Name: Bharatt Chowrira, PhD, J.D.  
Title: President  
Date: 9/1/2021

**PURETECH HEALTH LLC (“Assignee”)**

By:   
575C896D138A48D...  
Name: Bharatt Chowrira, PhD, J.D.  
Title: President  
Date: 9/1/2021

**ANNEX A****THE ASSIGNED PATENT APPLICATIONS**

<b>Country</b>	<b>Application Number</b>	<b>Filing Date</b>	<b>Title</b>
United States	62/896,235	5-Sep-2019	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR
United States	62/959,648	10-Jan-2020	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR
United States	PCT/US2020/014858	23-Jan-2020	ANTIBODIES SPECIFIC TO DELTA 1 CHAIN OF T CELL RECEPTOR